688621
vs
S
Shanghai Composite
688621
Over the past 12 months, Beijing Sun-Novo Pharmaceutical Research Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +88% compared to the Shanghai Composite's +28% growth.
Stocks Performance
688621 vs Shanghai Composite
Performance Gap
688621 vs Shanghai Composite
Performance By Year
688621 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Glance View
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. engages in the research and development of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 873 full-time employees. The company went IPO on 2021-06-21. The firm's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The firm mainly conducts its businesses in the domestic market.
